Monte Rosa Therapeutics, Inc. (GLUE)
USD 6.49
(-3.57%)
USD 6.49
(-3.57%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 6.22 Million | 8.55 Million | 2.13 Million | 537 Thousand | 72 Thousand |
| Gross Profit | -6.22 Million | -8.55 Million | -2.13 Million | -537 Thousand | -72 Thousand |
| Operating Expenses | 143.31 Million | 112.38 Million | 72.88 Million | 28.01 Million | 7.99 Million |
| Selling, General and Administrative Expenses | 32.03 Million | 27.32 Million | 15.72 Million | 4 Million | 644 Thousand |
| Research and Development Expenses | 111.27 Million | 85.06 Million | 57.15 Million | 24 Million | 7.35 Million |
| Other Expenses | - | - | -960 Thousand | -7.68 Million | 276 Thousand |
| Cost and Expenses | 143.31 Million | 112.38 Million | 72.88 Million | 28.01 Million | 7.99 Million |
| Operating Income | -143.31 Million | -112.38 Million | -72.88 Million | -28.01 Million | -7.99 Million |
| Interest Expense | - | 3.76 Million | - | - | 1000.00 |
| Income Tax Expense | 338 Thousand | -3.88 Million | -2.01 Million | 189 Thousand | 277 Thousand |
| Earnings before Tax | -135.01 Million | -108.5 Million | -73.95 Million | -35.87 Million | -7.74 Million |
| Net Income | -135.35 Million | -104.61 Million | -71.94 Million | -36.06 Million | -8.01 Million |
| Earnings Per Share Basic | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Earnings Per Share Diluted | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Weighted Average Shares Outstanding | 51.39 Million | 47.22 Million | 46.53 Million | 44 Million | 44 Million |
| Weighted Average Shares Outstanding (Diluted) | 51.39 Million | 47.22 Million | 46.53 Million | 44 Million | 44 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -137.08 Million | -99.94 Million | -70.75 Million | -27.47 Million | -7.66 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 4.69 Million | 1.06 Million | 8.75 Million | - | - | - |
| Cost of Revenue | 2.06 Million | 1.89 Million | 1.84 Million | 6.22 Million | 1.83 Million | 1.39 Million |
| Gross Profit | 2.63 Million | -833 Thousand | 6.9 Million | -6.22 Million | -1.83 Million | -1.39 Million |
| Operating Expenses | 35.27 Million | 34.11 Million | 33.01 Million | 137.08 Million | 36.96 Million | 37.22 Million |
| Selling, General and Administrative Expenses | 9.28 Million | 8.98 Million | 7.72 Million | - | 8.66 Million | 8.14 Million |
| Research and Development Expenses | 25.99 Million | 25.12 Million | 25.28 Million | - | 28.3 Million | 29.07 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 37.33 Million | 36.01 Million | 34.86 Million | 143.31 Million | 36.96 Million | 37.22 Million |
| Operating Income | -32.64 Million | -34.94 Million | -34.86 Million | -143.31 Million | -36.96 Million | -37.22 Million |
| Interest Expense | - | - | 935 Thousand | - | - | - |
| Income Tax Expense | 252 Thousand | 83 Thousand | -22 Thousand | 338 Thousand | -170 Thousand | 190 Thousand |
| Earnings before Tax | -30.05 Million | -31.88 Million | -33.27 Million | -135.01 Million | -34.71 Million | -34.98 Million |
| Net Income | -30.31 Million | -31.96 Million | -33.25 Million | -135.35 Million | -34.88 Million | -35.17 Million |
| Earnings Per Share Basic | -0.43 | -0.53 | -0.58 | - | -0.70 | -0.71 |
| Earnings Per Share Diluted | -0.43 | -0.53 | -0.58 | - | -0.70 | -0.71 |
| Weighted Average Shares Outstanding | 71.23 Million | 60.15 Million | 56.92 Million | 51.39 Million | 49.81 Million | 49.43 Million |
| Weighted Average Shares Outstanding (Diluted) | 71.23 Million | 60.15 Million | 56.92 Million | 51.39 Million | 49.81 Million | 49.43 Million |
| Gross Margin | 0.56 | -0.78 | 0.79 | - | - | - |
| EBIT Margin | -6.51 | -31.06 | -3.77 | - | - | - |
| Profit Margin | -6.46 | -30.05 | -3.80 | - | - | - |
| EBITDA | -30.58 Million | -33.04 Million | -33.01 Million | - | -36.96 Million | -35.76 Million |
| Earnings Before Tax Margin | -6.95 | -32.84 | -3.98 | - | - | - |
CPHN
0IUX
NOTE-WT
KARIN
IDN
3167